Oxbryta Safe and Effective in Children Ages 4 to 11, Early Trial Data Indicates

Oxbryta Safe and Effective in Children Ages 4 to 11, Early Trial Data Indicates

294217

Oxbryta Safe and Effective in Children Ages 4 to 11, Early Trial Data Indicates

Six months of treatment with Oxbryta (voxelotor) safely and effectively increased hemoglobin levels and reduced red blood cell destruction, or hemolysis, in children ages 4–11 with sickle cell disease (SCD), according to data from the ongoing Phase 2 HOPE-KIDS 1 trial. These findings are consistent with those previously reported for adolescents and adults with SCD given Oxbryta in the Phase 3 HOPE study (NCT03036813), which supported the therapy’s conditional approval for patients, ages 12 and older,…

You must be logged in to read/download the full post.